Gastrointestinal Side Effects with Resmetirom
While the FDA label does not provide exact percentages of patients experiencing nausea or gastrointestinal side effects, the exposure-adjusted incidence rates show nausea occurs in 18 per 100 person-years for the 80 mg dose and 15 per 100 person-years for the 100 mg dose, with symptoms typically resolving within 26-28 days of continued use. 1
Incidence of Gastrointestinal Side Effects
The gastrointestinal adverse reactions with resmetirom are dose-dependent and occur early in treatment:
- Diarrhea has exposure-adjusted incidence rates of 23 per 100 person-years (80 mg dose) and 33 per 100 person-years (100 mg dose), compared to 14 per 100 person-years with placebo 1
- Nausea has exposure-adjusted incidence rates of 18 per 100 person-years (80 mg dose) and 15 per 100 person-years (100 mg dose), compared to 9 per 100 person-years with placebo 1
- Vomiting occurs at 7 per 100 person-years (80 mg) and 8 per 100 person-years (100 mg) 1
- Constipation occurs at 5 per 100 person-years (80 mg) and 8 per 100 person-years (100 mg) 1
- Abdominal pain occurs at 5 per 100 person-years (80 mg) and 7 per 100 person-years (100 mg) 1
In real-world clinical practice, 41% of patients reported adverse events, predominantly gastrointestinal symptoms and pruritus 2
Timeline and Resolution of Symptoms
Nausea
- Onset timing is dose-dependent: median time to onset is 28 days for the 80 mg dose versus 5 days for the 100 mg dose 3
- Duration: Mean duration is 26 days (80 mg dose) and 28 days (100 mg dose) 3
- Severity: Nausea is mild to moderate in severity 1
Diarrhea
- Onset timing: Median time to onset is 17 days (80 mg dose) and 6 days (100 mg dose) 3
- Duration: Median duration is 20 days for both dose groups 3
- Severity: Diarrhea is typically mild to moderate 1
Treatment Discontinuation Rates
Diarrhea and nausea led to treatment discontinuation in 8 per 100 person-years in the high-dose (100 mg) group 3
In real-world experience, 16% of patients discontinued resmetirom after an average of 25.5 days, with 11 of 13 discontinuations due to adverse events including nausea, diarrhea, and vomiting 2
Clinical Management Recommendations
Patient Education Strategy
Education of patients on potential gastrointestinal disorders is recommended to avoid unnecessary treatment discontinuations and increase treatment persistence rates in real-world settings 3
Key counseling points include:
- Gastrointestinal symptoms are expected early in treatment and are typically self-limited 3
- Symptoms generally resolve within 20-28 days with continued use 3
- The symptoms are mild to moderate in severity 1
Monitoring Timeline
- Week 12 assessment: Reserved to confirm absence of drug-induced liver injury, not for efficacy assessment 3
- 6-month assessment: Disease monitoring with consideration to discontinue if gastrointestinal symptoms are debilitating 3
- 12-month assessment: Full efficacy evaluation 3
Important Clinical Pitfalls
Do not discontinue treatment before Week 12 based solely on gastrointestinal symptoms unless they are debilitating, as these symptoms are expected to resolve with continued use 3
The high discontinuation rate observed in real-world practice (16%) may be mitigated by modifying the approach from "prescribe and forget" to "prescribe and closely follow" 2
The overall gastrointestinal adverse reaction rates were 73 per 100 person-years (80 mg dose) and 89 per 100 person-years (100 mg dose), compared to 57 per 100 person-years with placebo 1